{
    "nct_id": "NCT03727880",
    "official_title": "A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)",
    "inclusion_criteria": "* Age ≥18 years.\n* Has pancreatic ductal adenocarcinoma\n* Has resectable disease at the time of diagnosis\n* Has not received any systemic therapy for pancreatic ductal adenocarcinoma\n* Has stage ≤ IIb disease at time of diagnosis and enrollment\n* Elevated tumor marker, CA (carbohydrate antigen) 19-9 >200\n* ECOG performance status 0 or 1\n* Patient must have adequate organ function defined by the study-specified laboratory tests.\n* Must use acceptable form of birth control while on study.\n* Ability to understand and willingness to sign a written informed consent document.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "Patients who have received any prior chemotherapy, radiotherapy or investigational agents for pancreatic cancer.\n\n* Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).\n* Has received prior therapy with FAK inhibitor.\n* Woman who are pregnant or breastfeeding.\n* Have received a live vaccine or live-attenuated vaccine within 30 days prior to study drug.\n* Is currently or has participated in another investigational study within 4 weeks prior to receiving study drug.\n* History or current use of immunosuppressive medications within 7 days prior to study medications.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years or that is expected to require active treatment within two years.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has a history of (non-infectious) pneumonitis/interstitial lung disease or current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Infection with HIV or hepatitis B or C.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Known allergy or hypersensitivity to the study drugs.\n* Received any growth factors including, but not limited to, granulocyte-colony stimulating factor (G-CSF), GM-CSF, erythropoietin, within 14 days of study drug administration.\n* Has history of any organ transplant, including corneal transplants.",
    "miscellaneous_criteria": ""
}